{
    "nctId": "NCT00063570",
    "briefTitle": "Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy",
    "officialTitle": "Phase II Trial of Alimta (Pemetrexed) and Gemzar (Gemcitabine) in Metastatic Breast Cancer Patients Who Have Received Prior Taxane Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 73,
    "primaryOutcomeMeasure": "Overall Tumor Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel).\n* Less than 3 different chemotherapy treatments for metastatic disease.\n* Prior treatment with hormonal and/or radiation therapy.\n* Must have disease that can be measured.\n* Must be able to take care of self needs for example personal hygiene\n\nExclusion Criteria:\n\n* Must not be pregnant or breast-feeding.\n* Cancer that has spread to the brain.\n* Treatment with Gemcitabine or Pemetrexed\n* Unable to take folic acid or Vitamin B12\n* Treatment for another cancer within the last 5 years",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}